Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery
Solid Biosciences Inc. (Nasdaq: SLDB) announced that CEO Bo Cumbo will participate in a panel discussion titled “Innovative AAVs Targeting Diverse Tissues” during the BMO Biopharma Spotlight Series on March 28, 2023, at 9:00 AM ET. The live event is exclusive to BMO clients, with a replay available later on the Company’s website. Solid Biosciences is focused on developing genetic medicines for neuromuscular and cardiac diseases, with key programs including SGT-003 for Duchenne and AVB-401 for dilated cardiomyopathy. The Company aims to improve patients' lives through scientific and technological advancement.
- None.
- None.
CHARLESTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the BMO Biopharma Spotlight Series: Genetic Medicine Delivery in a panel discussion titled “Innovative AAVs Targeting Diverse Tissues” on Tuesday, March 28, 2023 at 9:00 AM ET.
The event will be made available live only to clients of BMO. Following the event, a replay of the panel discussion will be available on the Events page of the Investors section of the Company website.
Institutional investors interested in meeting with management during the conference may reach out to their BMO representative.
About Solid Biosciences
Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate for the treatment of Duchenne, AVB-202-TT, a gene transfer candidate for the treatment of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Solid aims to be the center of excellence, bringing together those with expertise in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Solid Biosciences Media Contact:
Tim Palmer
Associate Director, Corporate Communications
607-760-4223
Tim@solidbio.com
FAQ
What is the date and time of the BMO Biopharma Spotlight Series featuring SLDB?
Who from SLDB will be participating in the BMO Biopharma event?
What is the focus of Solid Biosciences as a company?
Will the panel discussion featuring SLDB be available for replay?
What specific programs are highlighted by SLDB in the press release?
